The FDA is updating azithromycin drug labels to reflect evidence that the medication can contribute to a rare heart rhythm abnormality known as torsades de pointes.

Drugmaker Zydus Cadila on May 13 announced it had received final approval from the FDA to market chlorthalidone tablets, the generic equivalent of Pfizer’s now-discontinued hypertension drug Thalitone.

Low-dose daily aspirin may be effective as a preventive therapy for heart patients with symptomatic atherosclerotic disease, but in the general population the drug’s risk of intracranial bleeding outweighs any CV benefits it may have, according to a study published May 13 in JAMA Neurology.

CVD-related fatalities in individuals under 75 years old are on the rise in the U.K. for the first time in five decades, the Guardian reported May 12.

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

A machine learning algorithm can now predict death and MI more accurately than certified cardiologists, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT in Lisbon, Portugal, this May.

“The results of this research are extremely exciting, as it will significantly impact clinical care,” reported study author Mishal Mendiratta-Lala, MD, with the division of abdominal radiology at Michigan Medicine in Ann Arbor.

A team funded by the National Institutes of Health has succeeded in growing human acellular vessels—implantable, bioengineered human blood vessels—to replace damaged vasculature in patients with end-stage kidney failure.